Table 3.
Univariate analysis.
| Dropout | ||||
|---|---|---|---|---|
| Variable | Overall, N = 92 † | No, N = 84 † | Yes, N = 8 † | p-Value ‡ |
| Age | 0.2 | |||
| Mean (SD) | 64 (12) | 64 (12) | 57 (16) | |
| Median (IQR) | 66 (55, 73) | 66 (57, 73) | 52 (44, 72) | |
| Gender | 0.15 | |||
| F | 48 (100%) | 46 (96%) | 2 (4.2%) | |
| M | 44 (100%) | 38 (86%) | 6 (14%) | |
| Neoplasm | 0.6 | |||
| Other cancers | 40 (100%) | 36 (90%) | 4 (10%) | |
| Colon | 26 (100%) | 23 (88%) | 3 (12%) | |
| Breast | 15 (100%) | 15 (100%) | 0 (0%) | |
| Lung | 11 (100%) | 10 (91%) | 1 (9.1%) | |
| Metastatic status | 0.15 | |||
| No | 48 (100%) | 46 (96%) | 2 (4.2%) | |
| Yes | 44 (100%) | 38 (86%) | 6 (14%) | |
| ECOG-PS | >0.9 | |||
| ECOG < 3 | 49 (100%) | 45 (92%) | 4 (8.2%) | |
| ECOG = 3 | 43 (100%) | 39 (91%) | 4 (9.3%) | |
| Televisits (n) | 0.032 | |||
| n | 92 | 84 | 8 | |
| Mean (SD) | 2.4 (2) | 2.2 (1.9) | 4.1 (2.9) | |
| MED | >0.9 | |||
| ≤60 | 40 (100%) | 37 (92%) | 3 (7.5%) | |
| >60 | 52 (100%) | 47 (90%) | 5 (9.6%) | |
| IV-Morphine | 0.4 | |||
| No | 87 (100%) | 80 (92%) | 7 (8.0%) | |
| Yes | 5 (100%) | 4 (80%) | 1 (20%) | |
| NP Drugs | 0.074 | |||
| No | 52 (57%) | 50 (60%) | 2 (25%) | |
| Yes | 40 (43%) | 34 (40%) | 6 (75%) | |
† n (%); ‡ Wilcoxon rank-sum test; Fisher’s exact test. Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group Performance Status; MED, morphine equivalent dose; IV-Morphine, intravenous morphine; NP, neuropathic pain.